Faendrich Biotech Secures RMB 30 Million Series A Funding to Advance Immune Cell Therapy Research and Clinical Applications

FAENDRIOH BIOTECH Completes RMB 30 Million Series A Financing with Investment from Beijing Yunhetaifeng Investment Management Co., Ltd.

According to publicly available information, FAENDRIOH BIOTECH, established in April 2020, is a provider of immune cell research and cell technology services. The company specializes in immune cell research, clinical application studies, and cell technology services. It has introduced cutting-edge autologous immune cell technology into China and collaborates with senior cell biology experts from both China and Germany. The aim is to innovate, transform, apply, and promote autologous immune cell technology within China, contributing to the development of the life and health industry.